# To Determine Maximum Tolerated Dose of BAY79-4620 in Patients With Advanced Solid Tumors

> **NCT01028755** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 12 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** BAY79-4620

## Key facts

- **NCT ID:** NCT01028755
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2015-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01028755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01028755, "To Determine Maximum Tolerated Dose of BAY79-4620 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01028755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*